Aprea Therapeutics (APRE) News Today → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free APRE Stock Alerts $5.20 -0.15 (-2.80%) (As of 04:27 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineInterim Report - January-March 2024finance.yahoo.com - April 26 at 12:21 PMAprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Updateamericanbankingnews.com - April 17 at 3:44 AMAprea Therapeutics’ Promising Cancer Drug Candidate Warrants Buy Ratingmarkets.businessinsider.com - April 12 at 8:25 PMAprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024globenewswire.com - April 10 at 12:00 PMAprea Therapeutics files to sell 4.39M shares of common stock for holdersmsn.com - April 3 at 5:26 PMAprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Ratingmarkets.businessinsider.com - March 28 at 7:07 AMBuy Rating Affirmed: Aprea Therapeutics Poised for Growth with Strong Pipeline Momentum into 2024markets.businessinsider.com - March 27 at 11:03 AMAPRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 26 at 3:01 PMAprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Updateglobenewswire.com - March 26 at 7:45 AMAprea Therapeutics: Strong Buy Rating on Robust Financials and Promising Drug Pipelinemarkets.businessinsider.com - March 20 at 7:11 AMAprea Therapeutics Secures Up to $34 Million in Groundbreaking Financing Dealmsn.com - March 18 at 10:03 AMAprea Therapeutics CFO buys $7,362 in company stockuk.investing.com - March 16 at 6:08 PMAprea Therapeutics director buys $50k of company stockuk.investing.com - March 16 at 6:08 PMOren Gilad Acquires 2,000 Shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) Stockinsidertrades.com - March 15 at 12:00 PMKarolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 millionfinance.yahoo.com - March 14 at 10:33 AMKarolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 millionglobenewswire.com - March 14 at 7:48 AMAprea Therapeutics Secures Private Placement Financing Of Upto $34 Mlnmarkets.businessinsider.com - March 12 at 10:16 AMWhy Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?msn.com - March 11 at 2:00 PMAprea Therapeutics announces private placement financing of up to $34Mmsn.com - March 11 at 8:59 AMAprea Therapeutics Announces Private Placement Financing of up to $34.0 Millionglobenewswire.com - March 11 at 8:30 AMAprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancersglobenewswire.com - March 11 at 8:29 AMAprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024globenewswire.com - March 5 at 4:45 PMAprea Therapeutics Inc (APRE)uk.investing.com - February 23 at 3:13 PMAprea Therapeutics Inc.thestreet.com - February 7 at 11:54 PMAprea Therapeutics Updates Corporate Presentation Materialsmsn.com - February 7 at 1:49 PMAprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitorfinance.yahoo.com - February 6 at 9:57 AMBiotechnology Center in Doylestown Seeks State Funding to Continue Support for Life Science Start-Upsmsn.com - January 31 at 8:06 PMAprea Therapeutics to Present at DDR Inhibitors Summit 2024finance.yahoo.com - January 30 at 10:14 AMBuy Rating Affirmed for Aprea Therapeutics Amid Strong Clinical Results and Strategic Advantagesmarkets.businessinsider.com - January 12 at 8:13 PMWill Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?finance.yahoo.com - January 10 at 9:46 AMAnalysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), Enanta Pharmaceuticals (ENTA)markets.businessinsider.com - January 5 at 9:13 PMMaxim Group Keeps Their Hold Rating on Brainstorm Cell Therapeutics (BCLI)markets.businessinsider.com - December 9 at 9:09 AMCapricor Therapeutics: Solid Financials and Promising DMD Trial Progression Support Buy Ratingmarkets.businessinsider.com - November 17 at 10:15 AMVistaGen Therapeutics’ Robust Financial Position and Promising Pipeline Underpin Buy Rating: A Comprehensive Analysismarkets.businessinsider.com - November 12 at 7:58 AMPromising Clinical Data and Financial Performance Validate Buy Rating for Aprea Therapeutics: An Analysis by Robert Driscollmarkets.businessinsider.com - November 11 at 5:06 PMAprea Therapeutics GAAP EPS of -$0.86msn.com - November 9 at 6:05 PMAprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Updatefinance.yahoo.com - November 9 at 6:05 PMmarketbeat.com - October 20 at 9:41 AMmarketbeat.com - October 20 at 9:36 AMPositive Outlook for Aprea Therapeutics: Promising Developments and Safety Profile of ATRN-119 Bolster Buy Ratingmarkets.businessinsider.com - October 16 at 1:42 PMAprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfoliofinance.yahoo.com - October 16 at 8:42 AMPromising Outlook for Aprea Therapeutics: A Buy Rating Based on Upcoming Safety Data and Synthetic Lethal Targeting Potentialmarkets.businessinsider.com - October 6 at 3:11 PMAprea Therapeutics (APRE) Gets a Buy from Maxim Groupmarkets.businessinsider.com - September 21 at 8:30 AMAprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeuticsfinance.yahoo.com - September 19 at 11:11 AMAprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitorsfinance.yahoo.com - September 11 at 7:21 PMAprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 5:58 PMMyelodysplastic Syndrome Drugs Global Market Report 2023finance.yahoo.com - August 24 at 12:51 PMAprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairmanfinance.yahoo.com - August 24 at 12:51 PMAprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operationsfinance.yahoo.com - August 10 at 8:26 AMRLFTF Relief Therapeutics Holding AGseekingalpha.com - August 1 at 5:01 AM Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Move Your Money Before May 22 (Ad)The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. APRE Media Mentions By Week APRE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APRE News Sentiment▼0.000.33▲Average Medical News Sentiment APRE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APRE Articles This Week▼01▲APRE Articles Average Week Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: THTX News Today CASI News Today LEXX News Today JAN News Today SPRB News Today VIRX News Today FBIO News Today IPA News Today VYNE News Today APM News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APRE) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
